<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002786</url>
  </required_header>
  <id_info>
    <org_study_id>1017.01</org_study_id>
    <secondary_id>FHCRC-1017.01</secondary_id>
    <secondary_id>NCI-V96-0920</secondary_id>
    <secondary_id>CDR0000064846</secondary_id>
    <nct_id>NCT00002786</nct_id>
    <nct_alias>NCT00029419</nct_alias>
  </id_info>
  <brief_title>Biological Therapy in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>PHASE I STUDY TO EVALUATE THE SAFETY OF CELLULAR ADOPTIVE IMMUNOTHERAPY USING GENETICALLY MODIFIED AND UNMODIFIED AUTOLOGOUS CD8+ TYROSINASE-SPECIFIC T CELLS FOR PATIENTS WITH METASTATIC MELANOMA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies use different ways to stimulate the immune system and stop&#xD;
      cancer cells from growing.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effectiveness of biological therapy in treating&#xD;
      patients who have metastatic melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Assess the safety and toxicity of cellular adoptive immunotherapy using autologous CD8+&#xD;
           antigen-specific T-cell clones in patients with metastatic melanoma.&#xD;
&#xD;
        -  Estimate the duration of in vivo persistence of adoptively transferred CD8+&#xD;
           antigen-specific cytotoxic T-cell clones in these patients.&#xD;
&#xD;
        -  Evaluate the antitumor effects of CD8+ antigen-specific T-cell clones in these patients.&#xD;
&#xD;
      OUTLINE: Autologous peripheral blood mononuclear cells are harvested and then CD8+ cytotoxic&#xD;
      T-lymphocyte (CTL) clones targeting melanosomal antigens are generated ex vivo. Patients&#xD;
      receive cellular adoptive immunotherapy comprising autologous CD8+ CTL clones over 30 minutes&#xD;
      on day 1. Patients also receive interleukin-2 subcutaneously every 12 hours on days 1-14 of&#xD;
      courses 2-3. Treatment repeats every 3 weeks for 3 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed for approximately 1 year after the last infusion.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 20 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1995</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic tumor infiltrating lymphocytes</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histopathologically proven metastatic melanoma&#xD;
&#xD;
               -  No CNS metastases&#xD;
&#xD;
          -  HLA-A2 positive&#xD;
&#xD;
          -  Bidimensionally measurable disease by palpation on clinical exam or radiographic&#xD;
             imaging (x-ray, CT scan, or MRI)&#xD;
&#xD;
          -  Surgically accessible site for tumor cell procurement (skin, subcutaneous nodule, or&#xD;
             superficial node) and patient clinically eligible for such surgery&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 75&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 80-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 16 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC greater than 4,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count greater than 2,000/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Hematocrit greater than 30%&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.6 mg/dL&#xD;
&#xD;
          -  SGOT no greater than 150 IU (or no greater than 3 times normal)&#xD;
&#xD;
          -  Prothrombin time no greater than 1.5 times control&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
          -  Calcium no greater than 12 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No clinically significant hypotension&#xD;
&#xD;
          -  No symptoms of coronary artery disease&#xD;
&#xD;
          -  No arrhythmia on EKG requiring drug therapy&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No severe chronic obstructive pulmonary disease&#xD;
&#xD;
          -  FEV_1 at least 1.0 L&#xD;
&#xD;
          -  DLCO at least 45% of predicted&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No active infection or oral temperature greater than 38.2 degrees C within 72 hours of&#xD;
             study&#xD;
&#xD;
          -  No systemic infection requiring chronic maintenance or suppressive therapy&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No history of seizures&#xD;
&#xD;
          -  No retinitis or choroiditis&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use adequate contraception&#xD;
&#xD;
          -  Peripheral blood samples available weekly for 4 consecutive weeks&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  At least 4 weeks since other prior immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  1 or 2 courses of cytoreductive chemotherapy allowed for bulky disease&#xD;
&#xD;
          -  At least 4 weeks since prior standard or investigational chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  At least 4 weeks since prior steroid therapy&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 4 weeks since other prior investigational drug therapy and recovered&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cassian Yee, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>May 23, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2003</study_first_posted>
  <last_update_submitted>May 6, 2010</last_update_submitted>
  <last_update_submitted_qc>May 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2010</last_update_posted>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

